Enfusion, Inc. (NYSE:ENFN) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP cut its holdings in Enfusion, Inc. (NYSE:ENFN) by 74.3% during the fourth quarter, HoldingsChannel reports. The fund owned 31,388 shares of the company’s stock after selling 90,779 shares during the period. ExodusPoint Capital Management LP’s holdings in Enfusion were worth $323,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. New York State Common Retirement Fund lifted its holdings in shares of Enfusion by 23.8% in the 4th quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock worth $19,848,000 after acquiring an additional 370,498 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in Enfusion during the fourth quarter worth $2,358,000. Impax Asset Management Group plc boosted its position in shares of Enfusion by 31.5% during the fourth quarter. Impax Asset Management Group plc now owns 890,000 shares of the company’s stock worth $9,167,000 after buying an additional 213,052 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Enfusion by 612.4% in the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock valued at $1,974,000 after buying an additional 178,821 shares in the last quarter. Finally, Royce & Associates LP raised its holdings in shares of Enfusion by 84.6% in the 4th quarter. Royce & Associates LP now owns 184,078 shares of the company’s stock valued at $1,896,000 after buying an additional 84,363 shares during the period. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

Enfusion Price Performance

ENFN stock opened at $10.81 on Monday. The business’s 50-day moving average is $11.11 and its two-hundred day moving average is $10.37. The firm has a market capitalization of $1.39 billion, a P/E ratio of 270.19, a P/E/G ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80.

Enfusion (NYSE:ENFN) last issued its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The firm had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. On average, analysts expect that Enfusion, Inc. will post 0.06 EPS for the current year.

Insider Transactions at Enfusion

In other Enfusion news, CFO Bradley Herring sold 4,645 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $52,860.10. Following the sale, the chief financial officer now owns 324,689 shares of the company’s stock, valued at approximately $3,694,960.82. This trade represents a 1.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Neal Pawar sold 14,560 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $165,692.80. Following the completion of the transaction, the chief operating officer now owns 1,217,067 shares of the company’s stock, valued at approximately $13,850,222.46. The trade was a 1.18 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 66,223 shares of company stock valued at $754,778. Insiders own 36.44% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Piper Sandler lifted their target price on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus lifted their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, William Blair reiterated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.